Program Description & Educational Objectives

In this activity, an expert in non–small-cell lung cancer (NSCLC) addresses three key questions on the use of biomarkers to guide therapy selection, appropriate algorithms for NSCLC based on tumor histology, and the role of EGFR inhibition in first-line therapy for advanced NSCLC.

Upon completion of this activity, participants should be better able to:

• Discuss the role of biomarkers in the management of patients with NSCLC, particularly with regard to the treatment algorithm
• Evaluate the relative safety and efficacy of novel targeted and chemotherapeutic agents in the management of NSCLC
• Explain the role of targeted therapies in the management of early and advanced NSCLC, based on current clinical data

Target Audience

This activity has been designed to meet the educational needs of oncologists and other healthcare professionals engaged in the care of patients with NSCLC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: September 15, 2011 - September 14, 2012
Time to Complete: 15 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Interviewee

Howard (Jack) West, MD
Medical Oncologist
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

Howard (Jack) West, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

CME Reviewer

Thomas J. George, MD, FACP
Division of Hematology/Oncology
Assistant Professor
Director, Gastrointestinal Oncology Program
Associate Director, Fellowship Training Program
University of Florida
Gainesville, Florida

Thomas J. George, MD, FACP, currently has no financial interests/relationships or affiliations in relation to this activity.

Content Director

Annette Wiggins
Answers in CME, Inc.

Annette Wiggins currently has no financial interests/relationships or affiliations in relation to this activity.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and Answers in CME. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is jointly sponsored by the University of Florida College of Medicine and Answers in CME.

This activity is supported by an educational grant from Genentech, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.